Ligand validation:2BXM

IMN: INDOMETHACIN

IMN is a Ligand Of Interest in 2BXM designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2BXM_IMN_A_2001	35%	22%	0.217	0.906	2.01	1.27	6	4	2	0	100%	1
2BXM_IMN_A_2002	10%	26%	0.299	0.805	1.89	1.15	8	2	1	0	100%	1
2BXQ_IMN_A_2001	27%	23%	0.223	0.873	2.08	1.15	7	4	0	0	100%	1
2BXK_IMN_A_2001	22%	28%	0.226	0.843	1.96	0.94	4	1	2	0	100%	1
4YIA_IMN_B_401	71%	11%	0.101	0.922	1.42	2.71	3	14	0	0	100%	1
7FCG_IMN_A_200	66%	20%	0.115	0.919	1.56	1.85	5	8	1	0	100%	0.792
3UG8_IMN_A_2001	62%	10%	0.136	0.928	2.25	2.04	8	12	4	0	100%	0.7
4COX_IMN_A_701	61%	22%	0.155	0.945	1.87	1.37	7	2	8	0	100%	1
4JQ4_IMN_A_401	57%	12%	0.103	0.878	2.25	1.85	11	7	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.